BiotechTube

Atezolizumab + Bevacizumab + Tiragolumab

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatocellular Carcinoma

Conditions

Hepatocellular Carcinoma

Trial Timeline

Sep 14, 2023 → Sep 1, 2026

NCT ID
NCT05904886

About Atezolizumab + Bevacizumab + Tiragolumab

Atezolizumab + Bevacizumab + Tiragolumab is a phase 3 stage product being developed by Chugai Pharmaceutical for Hepatocellular Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05904886. Target conditions include Hepatocellular Carcinoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05904886Phase 3Active

Competing Products

20 competing products in Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
25
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
25
Ramucirumab + PlaceboEli LillyPhase 3
77
ERY974 + Tocilicumab + Atezolizumab + BevacizumabChugai PharmaceuticalPhase 1
33
GC33(RO5137382) + SorafenibChugai PharmaceuticalPhase 1
33
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kgDaiichi SankyoPhase 2
52
Tivantinib + PlaceboDaiichi SankyoPhase 3
77
OSI-906 + PlaceboAstellas PharmaPhase 2
52
Enzalutamide + PlaceboAstellas PharmaPhase 2
52
Enzalutamide + Enzalutamide with SorafenibAstellas PharmaPhase 1
33
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
33
Irinotecan + Sonidegib + SorafenibSun PharmaceuticalPhase 2
52
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
52
camrelizumab& apatinibSun PharmaceuticalPhase 2
52
LenvatinibEisaiPre-clinical
23
Lenvatinib PillEisaiPhase 2
52
Sorafenib + SorafenibEisaiPhase 1/2
41
LenvatinibEisaiPhase 2
52
Lenvatinib + NivolumabEisaiPhase 2
52
H3B-6527EisaiPhase 1
33

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved
85
Pegasys® + Pegasys®Approved
85
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3
77
R744 + Epoetin betaPhase 3
77
EmicizumabPhase 3
77